Placebo (vehicle) nasal spray
Sponsors
Oyster Point Pharma, Inc., Brandon Baartman, Vance Thompson Vision ND, Vance Thompson Vision - MT, Center for Ophthalmic and Vision Research, LLC
Conditions
Dry EyeDry Eye DiseaseDry Eye Disease (DED)Long Term Follow up Dry Eye DiseaseNeurotrophic Keratopathy
Phase 2
Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
CompletedNCT03452397
Start: 2018-02-27End: 2018-04-27Updated: 2021-12-14
Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
CompletedNCT03633461
Start: 2018-08-14End: 2018-09-20Updated: 2022-03-09
Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
CompletedNCT03636061
Start: 2018-08-15End: 2018-09-26Updated: 2021-10-25
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
CompletedNCT03920215
Start: 2018-08-15End: 2019-09-20Updated: 2023-11-01
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
CompletedNCT04957758
Start: 2021-06-17End: 2023-04-28Updated: 2024-05-07
IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL
NCT05136924
Start: 2021-12-01End: 2022-06-01Target: 20Updated: 2021-11-30
Phase 3
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
CompletedNCT04036292
Start: 2019-07-23End: 2021-02-05Updated: 2021-11-22
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)
NCT05045508
Start: 2021-08-30End: 2023-01-30Target: 60Updated: 2021-09-22
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
CompletedNCT05082974
Start: 2021-10-20End: 2022-08-03Updated: 2023-06-12